Localized delivery of growth factors for bone repair

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 58, Issue 2, 2004, Pages 197-208

  Luginbuehl, Vera ^a   Meinel, Lorenz ^a   Merkle, Hans P ^a   Gander, Bruno ^a,b  

^a ETH ZURICH   (Switzerland)

^b Swiss Fed Inst Technol Z   (Switzerland)

Author keywords

aFGF, acidic fibroblast growth factor; bFGF, basic fibroblast growth factor; BMP, bone morphogenetic protein; Bone repair; Clinical safety; Controlled delivery; Dose effects; Drug delivery; Growth factors; Localized delivery; Release kinetics

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; COLLAGEN; GROWTH FACTOR; OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1;

BONE REMODELING; CHEMICAL MODIFICATION; COMMERCIAL PHENOMENA; COVALENT BOND; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; HUMAN; KINETICS; NONHUMAN; PROTEIN IMMOBILIZATION; REVIEW; SIDE EFFECT; STANDARDIZATION; TOXICITY;

ANIMALS; BONE DISEASES; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GROWTH SUBSTANCES; HUMANS; KINETICS; RECOMBINANT FUSION PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 3843150535     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2004.03.004     Document Type: Review

References (131)

1. Einhorn T.A. The cell and molecular biology of fracture healing. Clin. Orthop. 1998;S7-S21
2. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16:1995;3-34
3. Miyazono K. Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone. 25:1999;91-93
4. Heldin C.H., Miyazono K., ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 390:1997;465-471
5. Bauer T.W., Muschler G.F. Bone graft materials. An overview of the basic science. Clin. Orthop. 2000;10-27
6. Lind M. Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation. Acta Orthop. Scand. Suppl. 283:1998;2-37
7. Khan S.N., Bostrom M.P., Lane J.M. Bone growth factors. Orthop. Clin. North. Am. 31:2000;375-388
8. Lieberman J.R., Daluiski A., Einhorn T.A. The role of growth factors in the repair of bone. Biology and clinical applications. J. Bone Joint Surg. Am. 84-A:2002;1032-1044
9. Putney S.D., Burke P.A. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 16:1998;153-157
10. Tabata Y. Tissue regeneration based on growth factor release. Tissue Eng. 9:(Suppl. 1):2003;S5-S15
11. Kirker-Head C.A. Potential applications and delivery strategies for bone morphogenetic proteins. Adv. Drug Deliv. Rev. 43:2000;65-92
12. Urist M.R. Bone: formation by autoinduction. Science. 150:1965;893-899
13. Rodan G.A. Skeletal Growth Factors. 2000;Lippincott Williams & Wilkins, Philadelphia, PA
14. http://www.op1.com/index.cfm, http://www.medtronicsofamordanek.com/.
15. Mark Saltzman W., Baldwin S.P. Materials for protein delivery in tissue engineering. Adv. Drug Deliv. Rev. 33:1998;71-86
16. LeGeros R.Z. Properties of osteoconductive biomaterials: calcium phosphates. Clin. Orthop. 2002;81-98
17. Winn S.R., Uludag H., Hollinger J.O. Carrier systems for bone morphogenetic proteins. Clin. Orthop. 1999;S95-S106
18. Meinel L., Kareourgiou V., Fajardo R., Snyder B., Shinde-Patil V., Zichner L., Kaplan D., Langer R., Vunjak-Novakovic G. Bone tissue engineering using human mesenchymal stem cells: effects of scaffold material and medium flow. Ann. Biomed. Eng. 32:2004;112-122
19. Nunamaker D.M. Experimental models of fracture repair. Clin. Orthop. 1998;S56-S65
20. Tabata Y., Yamada K., Miyamoto S., Nagata I., Kikuchi H., Aoyama I., Tamura M., Ikada Y. Bone regeneration by basic fibroblast growth factor complexed with biodegradable hydrogels. Biomaterials. 19:1998;807-815
21. Stenport V.F., Roos-Jansaker A.M., Renvert S., Kuboki Y., Irwin C., Albrektsson T., Claffey N. Failure to induce supracrestal bone growth between and around partially inserted titanium implants using bone morphogenetic protein (BMP): an experimental study in dogs. Clin. Oral Implants Res. 14:2003;219-225
22. Kirkeby O.J., Ekeland A. No effects of local somatomedin C on bone repair. Continuous infusion in rats. Acta Orthop. Scand. 63:1992;447-450
23. Aspenberg P., Albrektsson T., Thorngren K.G. Local application of growth-factor IGF-1 to healing bone. Experiments with a titanium chamber in rabbits. Acta Orthop. Scand. 60:1989;607-610
24. L. Meinel, Delivery of insulin like growth factor I for bone repair, PhD Thesis, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zürich, 2001.
25. Li R.H., Wozney J.M. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol. 19:2001;255-265
26. Folkman J., Long D. The use of silicone rubber as a carrier for prolonged drug therapy. J. Surg. Res. 4:1964;139-142
27. Langer R., Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 263:1976;797-800
28. Schmidmaier G., Wildemann B., Stemberger A., Haas N.P., Raschke M. Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors. J. Biomed. Mater. Res. 58:2001;449-455
29. Riedel G.E., Valentin-Opran A. Clinical evaluation of rhBMP-2/ACS in orthopedic trauma: a progress report. Orthopedics. 22:1999;663-665
30. Hollinger J.O., Uludag H., Winn S.R. Sustained release emphasizing recombinant human bone morphogenetic protein-2. Adv. Drug Deliv. Rev. 31:1998;303-318
31. Ruoslahti E., Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell. 64:1991;867-869
32. Blanquaert F., Barritault D., Caruelle J.P. Effects of heparan-like polymers associated with growth factors on osteoblast proliferation and phenotype expression. J. Biomed. Mater. Res. 44:1999;63-72
33. Yayon A., Klagsbrun M., Esko J.D., Leder P., Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 64:1991;841-848
34. Ikada Y., Tabata Y. Protein release from gelatin matrices. Adv. Drug Deliv. Rev. 31:1998;287-301
35. Drobnik J. Hyaluronan in drug delivery. Adv. Drug Deliv. Rev. 7:1991;295-308
36. Chornet E., Dumitriu S. Inclusion and release of proteins from polysaccharide-based polyion complexes. Adv. Drug Deliv. Rev. 31:1998;223-246
37. Mumper R.J., Hoffman A.S., Puolakkainen P., Bouchard L.S., Gombotz W.R. Calcium-alginate beads for the oral delivery of transforming growth factor-β1 (TGF-β1): stabilization of TGF-β1 by the addition of polyacrylic acid within acid-treated beads. J. Control. Release. 30:1994;241-251
38. Jen A., Madorin K., Vosbeck K., Arvinte T., Merkle H.P. Transforming growth factor beta-3 crystals as reservoirs for slow release of active TGF-beta3. J. Control. Release. 78:2002;25-34
39. Jen A., Merkle H.P. Diamonds in the rough: protein crystals from a formulation perspective. Pharm. Res. 18:2001;1483-1488
40. Merkle H.P., Jen A. A crystal clear solution for insulin delivery. Nat. Biotechnol. 20:2002;789-790
41. Kuhl P.R., Griffith-Cima L.G. Tethered epidermal growth factor as a paradigm for growth factor-induced stimulation from the solid phase. Nat. Med. 2:1996;1022-1027
42. Sofia S., McCarthy M.B., Gronowicz G., Kaplan D.L. Functionalized silk-based biomaterials for bone formation. J. Biomed. Mater. Res. 54:2001;139-148
43. Bentz H., Schroeder J.A., Estridge T.D. Improved local delivery of TGF-beta2 by binding to injectable fibrillar collagen via difunctional polyethylene glycol. J. Biomed. Mater. Res. 39:1998;539-548
44. Mann B.K., Schmedlen R.H., West J.L. Tethered-TGF-beta increases extracellular matrix production of vascular smooth muscle cells. Biomaterials. 22:2001;439-444
45. Suzuki Y., Tanihara M., Suzuki K., Saitou A., Sufan W., Nishimura Y. Alginate hydrogel linked with synthetic oligopeptide derived from BMP-2 allows ectopic osteoinduction in vivo. J. Biomed. Mater. Res. 50:2000;405-409
46. Uludag H., D'Augusta D., Golden J., Li J., Timony G., Riedel R., Wozney J.M. Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: a correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. J. Biomed. Mater. Res. 50:2000;227-238
47. Uludag H., Golden J., Palmer R., Wozney J.M. Biotinated bone morphogenetic protein-2: in vivo and in vitro activity. Biotechnol. Bioeng. 65:1999;668-672
48. Ruppert R., Hoffmann E., Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur. J. Biochem. 237:1996;295-302
49. Aono A., Hazama M., Notoya K., Taketomi S., Yamasaki H., Tsukuda R., Sasaki S., Fujisawa Y. Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem. Biophys. Res. Commun. 210:1995;670-677
50. Israel D.I., Nove J., Kerns K.M., Kaufman R.J., Rosen V., Cox K.A., Wozney J.M. Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors. 13:1996;291-300
51. Andrades J.A., Han B., Becerra J., Sorgente N., Hall F.L., Nimni M.E. A recombinant human TGF-beta1 fusion protein with collagen-binding domain promotes migration, growth, and differentiation of bone marrow mesenchymal cells. Exp. Cell Res. 250:1999;485-498
52. Yoneda A., Asada M., Oda Y., Suzuki M., Imamura T. Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity. Nat. Biotechnol. 18:2000;641-644
53. Cho T.J., Gerstenfeld L.C., Einhorn T.A. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J. Bone Miner. Res. 17:2002;513-520
54. Bourque W.T., Gross M., Hall B.K. Expression of four growth factors during fracture repair. Int. J. Dev. Biol. 37:1993;573-579
55. Andrew J.G., Hoyland J., Andrew S.M., Freemont A.J., Marsh D. Demonstration of TGF-beta 1 mRNA by in situ hybridization in normal human fracture healing. Calcif. Tissue Int. 52:1993;74-78
56. Babensee J.E., McIntire L.V., Mikos A.G. Growth factor delivery for tissue engineering. Pharm. Res. 17:2000;497-504
57. Tabata I.I. The importance of drug delivery systems in tissue engineering. Pharm. Sci. Technol. Today. 3:2000;80-89
58. Dinbergs I.D., Brown L., Edelman E.R. Cellular response to transforming growth factor-beta1 and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions. J. Biol. Chem. 271:1996;29822-29829
59. Talwar R., Di Silvio L., Hughes F.J., King G.N. Effects of carrier release kinetics on bone morphogenetic protein-2-induced periodontal regeneration in vivo. J. Clin. Periodontol. 28:2001;340-347
60. Uludag H., Gao T., Porter T.J., Friess W., Wozney J.M. Delivery systems for BMPs: factors contributing to protein retention at an application site. J. Bone Joint Surg. Am. 83-A:(Suppl. 1):2001;S128-S135
61. Langer R. New methods of drug delivery. Science. 249:1990;1527-1533
62. Fan L.T., Singh S.K. Controlled Release: A Quantitative Treatment. vol. 13:1989;Springer, Berlin. pp. 20-44
63. Whang K., Goldstick T.K., Healy K.E. A biodegradable polymer scaffold for delivery of osteotropic factors. Biomaterials. 21:2000;2545-2551
64. Demers C.N., Tabrizian M., Petit A., Hamdy R.C., Yahia L. Effect of experimental parameters on the in vitro release kinetics of transforming growth factor beta1 from coral particles. J. Biomed. Mater. Res. 59:2002;403-410
65. Ueda H., Hong L., Yamamoto M., Shigeno K., Inoue M., Toba T., Yoshitani M., Nakamura T., Tabata Y., Shimizu Y. Use of collagen sponge incorporating transforming growth factor-beta1 to promote bone repair in skull defects in rabbits. Biomaterials. 23:2002;1003-1010
66. Zellin G., Beck S., Hardwick R., Linde A. Opposite effects of recombinant human transforming growth factor-beta 1 on bone regeneration in vivo: effects of exclusion of periosteal cells by microporous membrane. Bone. 22:1998;613-620
67. Meinel L., Zoidis E., Zapf J., Hassa P., Hottiger M.O., Auer J.A., Schneider R., Gander B., Luginbuehl V., Bettschart-Wolfisberger R., Illi O.E., Merkle H.P., von Rechenberg B. Localized insulin like growth factor I delivery to enhance new bone formation. Bone. 33:2003;660-672
68. Meinel L., Illi O.E., Zapf J., Malfanti M., Peter Merkle H., Gander B. Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co-glycolide) microspheres. J. Control. Release. 70:2001;193-202
69. Laffargue P., Fialdes P., Frayssinet P., Rtaimate M., Hildebrand H.F., Marchandise X. Adsorption and release of insulin-like growth factor-I on porous tricalcium phosphate implant. J. Biomed. Mater. Res. 49:2000;415-421
70. Aspenberg P., Jeppsson C., Wang J.S., Bostrom M. Transforming growth factor beta and bone morphogenetic protein 2 for bone ingrowth: a comparison using bone chambers in rats. Bone. 19:1996;499-503
71. Jeppsson C., Aspenberg P. BMP-2 can inhibit bone healing. Bone-chamber study in rabbits. Acta Orthop. Scand. 67:1996;589-592
72. Valentin-Opran A., Wozney J., Csimma C., Lilly L., Riedel G.E. Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin. Orthop. 2002;110-120
73. Wang E.A., Rosen V., D'Alessandro J.S., Bauduy M., Cordes P., Harada T., Israel D.I., Hewick R.M., Kerns K.M., LaPan P., Luxenberg D.P., McQuaid D., Moutsatsos I.K., Nove J., Wozney J.M. Recombinant human bone morphogenetic protein induces bone formation. Proc. Natl. Acad. Sci. USA. 87:1990;2220-2224
74. Seeherman H., Wozney J., Li R. Bone morphogenetic protein delivery systems. Spine. 27:2002;S16-S23
75. Aspenberg P., Jeppsson C., Economides A.N. The bone morphogenetic proteins antagonist Noggin inhibits membranous ossification. J. Bone Miner. Res. 16:2001;497-500
76. Akamaru T., Suh D., Boden S.D., Kim H.S., Minamide A., Louis-Ugbo J. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion. Spine. 28:2003;429-434
77. Hollinger J.O., Leong K. Poly(alpha-hydroxy acids): carriers for bone morphogenetic proteins. Biomaterials. 17:1996;187-194
78. Sciadini M.F., Dawson J.M., Berman L.M. Dose-response characteristics of recombinant human bone morphogenetic protein-2 in a canine segmental defect model. Trans. ORS. 1995;594
79. Critchlow M.A., Bland Y.S., Ashhurst D.E. The effects of age on the response of rabbit periosteal osteoprogenitor cells to exogenous transforming growth factor-beta 2. J. Cell Sci. 107:(Pt 2):1994;499-516
80. Poynton A.R., Lane J.M. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine. 27:2002;S40-S48
81. Kanatani M., Sugimoto T., Kaji H., Kobayashi T., Nishiyama K., Fukase M., Kumegawa M., Chihara K. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J. Bone Miner. Res. 10:1995;1681-1690
82. Hill P.A., Tumber A., Meikle M.C. Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology. 138:1997;3849-3858
83. Friedlaender G.E., Perry C.R., Cole J.D., Cook S.D., Cierny G., Muschler G.F., Zych G.A., Calhoun J.H., LaForte A.J., Yin S. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J. Bone Joint Surg. Am. 83-A:(Suppl. 1):2001;S151-S158
84. Vaccaro A.R., Patel T., Fischgrund J., Anderson D.G., Truumees E., Herkowitz H., Phillips F., Hilibrand A., Albert T.J. A pilot safety and efficacy study of OP-1 putty (rhBMP-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur. Spine J. 12:2003;495-500
85. Sandberg M.M., Aro H.T., Vuorio E.I. Gene expression during bone repair. Clin. Orthop. 1993;292-312
86. Nuttall M.E. Drug discovery and target validation. Cells Tissues Organs. 169:2001;265-271
87. Hill C.S., Treisman R. Growth factors and gene expression: fresh insights from arrays. Sci. STKE. (1999):1999;PE1
88. Khaitan A., Seth A., Dinda A.K., Singh I., Talwar M., Bandhu S. Transurethral resection versus open surgery for leiomyoma of urinary bladder - a report of 2 cases. Int. Urogynecol. J. Pelvic Floor Dysfunct. 13:2002;270-273
89. Beck G.R. Jr., Zerler B., Moran E. Gene array analysis of osteoblast differentiation. Cell Growth Differ. 12:2001;61-83
90. Roman-Roman S., Garcia T., Jackson A., Theilhaber J., Rawadi G., Connolly T., Spinella-Jaegle S., Kawai S., Courtois B., Bushnell S., Auberval M., Call K., Baron R. Identification of genes regulated during osteoblastic differentiation by genome-wide expression analysis of mouse calvaria primary osteoblasts in vitro. Bone. 32:2003;474-482
91. Billiard J., Moran R.A., Whitley M.Z., Chatterjee-Kishore M., Gillis K., Brown E.L., Komm B.S., Bodine P.V. Transcriptional profiling of human osteoblast differentiation. J. Cell Biochem. 89:2003;389-400
92. de Jong D.S., van Zoelen E.J., Bauerschmidt S., Olijve W., Steegenga W.T. Microarray analysis of bone morphogenetic protein, transforming growth factor beta, and activin early response genes during osteoblastic cell differentiation. J. Bone Miner. Res. 17:2002;2119-2129
93. Jeong B., Gutowska A. Lessons from nature: stimuli-responsive polymers and their biomedical applications. Trends Biotechnol. 20:2002;305-311
94. Hoffman A.S., Stayton P.S., Bulmus V., Chen G., Chen J., Cheung C., Chilkoti A., Ding Z., Dong L., Fong R., Lackey C.A., Long C.J., Miura M., Morris J.E., Murthy N., Nabeshima Y., Park T.G., Press O.W., Shimoboji T., Shoemaker S., Yang H.J., Monji N., Nowinski R.C., Cole C.A., Priest J.H., Harris J.M., Nakamae K., Nishino T., Miyata T. Founder's Award, Society for Biomaterials. Sixth World Biomaterials Congress, Kamuela, HI, May 15-20, 2000. Really smart bioconjugates of smart polymers and receptor proteins. J. Biomed. Mater. Res. 52:2000;577-586
95. Lutolf M.P., Lauer-Fields J.L., Schmoekel H.G., Metters A.T., Weber F.E., Fields G.B., Hubbell J.A. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc. Natl. Acad. Sci. USA. 100:2003;5413-5418
96. Schmidmaier G., Wildemann B., Gabelein T., Heeger J., Kandziora F., Haas N.P., Raschke M. Synergistic effect of IGF-I and TGF-beta1 on fracture healing in rats: single versus combined application of IGF-I and TGF-beta1. Acta Orthop. Scand. 74:2003;604-610
97. Vonau R.L., Bostrom M.P., Aspenberg P., Sams A.E. Combination of growth factors inhibits bone ingrowth in the bone harvest chamber. Clin. Orthop. 2001;243-251
98. Raiche A.T., Puleo D.A. In vitro effects of combined and sequential delivery of two bone growth factors. Biomaterials. 25:2004;677-685
99. Richardson T.P., Peters M.C., Ennett A.B., Mooney D.J. Polymeric system for dual growth factor delivery. Nat. Biotechnol. 19:2001;1029-1034
100. Hirabayashi H., Fujisaki J. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin. Pharmacokinet. 42:2003;1319-1330
101. Uludag H., Yang J. Targeting systemically administered proteins to bone by bisphosphonate conjugation. Biotechnol. Prog. 18:2002;604-611
102. Yokogawa K., Miya K., Sekido T., Higashi Y., Nomura M., Fujisawa R., Morito K., Masamune Y., Waki Y., Kasugai S., Miyamoto K. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology. 142:2001;1228-1233
103. Kasugai S., Fujisawa R., Waki Y., Miyamoto K., Ohya K. Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J. Bone Miner. Res. 15:2000;936-943
104. Wang D., Miller S., Sima M., Kopeckova P., Kopecek J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug. Chem. 14:2003;853-859
105. Keegan M.E., Whittum-Hudson J.A., Mark Saltzman W. Biomimetic design in microparticulate vaccines. Biomaterials. 24:2003;4435-4443
106. Faraasen S., Voros J., Csucs G., Textor M., Merkle H.P., Walter E. Ligand-specific targeting of microspheres to phagocytes by surface modification with poly(L-lysine)-grafted poly(ethylene glycol) conjugate. Pharm. Res. 20:2003;237-246
107. Tosatti S., De Paul S.M., Askendal A., VandeVondele S., Hubbell J.A., Tengvall P., Textor M. Peptide functionalized poly(L-lysine)-g-poly(ethylene glycol) on titanium: resistance to protein adsorption in full heparinized human blood plasma. Biomaterials. 24:2003;4949-4958
108. Simmons P.J., Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood. 78:1991;55-62
109. Joyner C.J., Bennett A., Triffitt J.T. Identification and enrichment of human osteoprogenitor cells by using differentiation stage-specific monoclonal antibodies. Bone. 21:1997;1-6
110. Sakiyama H., Masuda R., Inoue N., Yamamoto K., Kuriiwa K., Nakagawa K., Yoshida K. Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. J. Bone Miner. Metab. 19:2001;220-227
111. Purpura K.A., Zandstra P.W., Aubin J.E. Fluorescence activated cell sorting reveals heterogeneous and cell non-autonomous osteoprogenitor differentiation in fetal rat calvaria cell populations. J. Cell Biochem. 90:2003;109-120
112. Johnson E.E., Urist M.R., Finerman G.A. Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein. A preliminary report. Clin. Orthop. 236:1988;249-257
113. Welch R.D., Jones A.L., Bucholz R.W., Reinert C.M., Tjia J.S., Pierce W.A., Wozney J.M., Li X.J. Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J. Bone Miner. Res. 13:1998;1483-1490
114. Kandziora F., Bail H., Schmidmaier G., Schollmeier G., Scholz M., Knispel C., Hiller T., Pflugmacher R., Mittlmeier T., Raschke M., Haas N.P. Bone morphogenetic protein-2 application by a poly(D,L-lactide)-coated interbody cage: in vivo results of a new carrier for growth factors. J. Neurosurg. 97:2002;40-48
115. Ripamonti U., Van Den Heever B., Sampath T.K., Tucker M.M., Rueger D.C., Reddi A.H. Complete regeneration of bone in the baboon by recombinant human osteogenic protein-1 (hOP-1, bone morphogenetic protein-7). Growth Factors. 13:1996;273-289
116. Stevenson S., Cunningham N., Toth J., Davy D., Reddi A.H. The effect of osteogenin (a bone morphogenetic protein) on the formation of bone in orthotopic segmental defects in rats. J. Bone Joint Surg. Am. 76:1994;1676-1687
117. Forslund C., Aspenberg P. CDMP-2 induces bone or tendon-like tissue depending on mechanical stimulation. J. Orthop. Res. 20:2002;1170-1174
118. McKinney L., Hollinger J.O. A bone regeneration study: transforming growth factor-beta 1 and its delivery. J. Craniofac. Surg. 7:1996;36-45
119. Beck L.S., Wong R.L., DeGuzman L., Lee W.P., Ongpipattanakul B., Nguyen T.H. Combination of bone marrow and TGF-beta1 augment the healing of critical-sized bone defects. J. Pharm. Sci. 87:1998;1379-1386
120. Critchlow M.A., Bland Y.S., Ashhurst D.E. The effect of exogenous transforming growth factor-beta 2 on healing fractures in the rabbit. Bone. 16:1995;521-527
121. Steffen T., Stoll T., Arvinte T., Schenk R.K. Porous tricalcium phosphate and transforming growth factor used for anterior spine surgery. Eur. Spine J. 10:(Suppl. 2):2001;S132-S140
122. Thaller S.R., Dart A., Tesluk H. The effects of insulin-like growth factor-1 on critical-size calvarial defects in Sprague-Dawley rats. Ann. Plast. Surg. 31:1993;429-433
123. Raschke M., Wildemann B., Inden P., Bail H., Flyvbjerg A., Hoffmann J., Haas N.P., Schmidmaier G. Insulin-like growth factor-1 and transforming growth factor-beta1 accelerates osteotomy healing using polylactide-coated implants as a delivery system: a biomechanical and histological study in minipigs. Bone. 30:2002;144-151
124. Toung J.S., Ogle R.C., Morgan R.F., Lindsey W.H. Insulinlike growth factor 1- and 2-augmented collagen gel repair of facial osseous defects. Arch. Otolaryngol. Head Neck Surg. 125:1999;451-455
125. Radomsky M.L., Aufdemorte T.B., Swain L.D., Fox W.C., Spiro R.C., Poser J.W. Novel formulation of fibroblast growth factor-2 in a hyaluronan gel accelerates fracture healing in nonhuman primates. J. Orthop. Res. 17:1999;607-614
126. Murakami S., Takayama S., Kitamura M., Shimabukuro Y., Yanagi K., Ikezawa K., Saho T., Nozaki T., Okada H. Recombinant human basic fibroblast growth factor (bFGF) stimulates periodontal regeneration in class II furcation defects created in beagle dogs. J. Periodontal Res. 38:2003;97-103
127. Cuevas P., de Paz V., Cuevas B., Marin-Martinez J., Picon-Molina M., Fernandez-Pereira A., Gimenez-Gallego G. Osteopromotion for cranioplasty: an experimental study in rats using acidic fibroblast growth factor. Surg. Neurol. 47:1997;242-246
128. Nash T.J., Howlett C.R., Martin C., Steele J., Johnson K.A., Hicklin D.J. Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone. 15:1994;203-208
129. Lee Y.M., Park Y.J., Lee S.J., Ku Y., Han S.B., Klokkevold P.R., Chung C.P. The bone regenerative effect of platelet-derived growth factor-BB delivered with a chitosan/tricalcium phosphate sponge carrier. J. Periodontol. 71:2000;418-424
130. Israel D.I., Nove J., Kerns K.M., Moutsatsos I.K., Kaufman R.J. Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells. Growth Factors. 7:1992;139-150
131. Lutolf M.P., Weber F.E., Schmoekel H.G., Schense J.C., Kohler T., Muller R., Hubbell J.A. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat. Biotechnol. 21:2003;513-518